GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » Capex-to-Revenue

Orion Infusions (DHA:ORIONINFU) Capex-to-Revenue : 0.04 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Orion Infusions Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Orion Infusions's Capital Expenditure for the three months ended in Dec. 2023 was BDT-8.49 Mil. Its Revenue for the three months ended in Dec. 2023 was BDT202.73 Mil.

Hence, Orion Infusions's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.04.


Orion Infusions Capex-to-Revenue Historical Data

The historical data trend for Orion Infusions's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions Capex-to-Revenue Chart

Orion Infusions Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.03 0.02 0.08

Orion Infusions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.04 0.29 - 0.04

Competitive Comparison of Orion Infusions's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Orion Infusions's Capex-to-Revenue falls into.



Orion Infusions Capex-to-Revenue Calculation

Orion Infusions's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-67.92) / 810.153
=0.08

Orion Infusions's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-8.492) / 202.732
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Orion Infusions  (DHA:ORIONINFU) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Orion Infusions Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Orion Infusions's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions (DHA:ORIONINFU) Business Description

Traded in Other Exchanges
N/A
Address
Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines